Claims for Patent: 10,487,330

Summary for Patent: 10,487,330

Title:	Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Abstract:	This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Inventor(s):	Brown; Bob D. (Littleton, MA), Dudek; Henryk T. (Wellesley, MA)
Assignee:	Dicerna Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	16/297,354
Patent Claims:	1. A nucleic acid comprising a first strand and a second strand forming a duplex structure, wherein the first strand is 21 nucleotides in length and the second strand is 23 nucleotides in length, wherein the second strand is 100% complementary along at least 15 nucleotides with the sequence as set forth in SEQ ID NO: 1823, wherein the second strand has a 3' overhang of 2 nucleotides in length. 2. The nucleic acid of claim 1, wherein the second strand comprises at least two phosphorothioate internucleotide linkages. 3. The nucleic acid of claim 1, wherein the first strand and/or second strands comprise one or more modified nucleotides. 4. The nucleic acid of claim 3, wherein each residue of the first strand and/or each residue of the second strand is a modified nucleotide. 5. The nucleic acid of claim 3, wherein each modified nucleotide is independently a 2'-O-methyl or 2'-fluoro modified nucleotide. 6. The nucleic acid of claim 1, wherein at least one nucleotide of the first strand is conjugated with one or more GalNac moieties. 7. The nucleic acid of claim 6, wherein the at least one nucleotide is conjugated to the 3' terminal nucleotide of the first strand. 8. The nucleic acid of claim 1, wherein the second strand is a guide strand that complexes with RISC, binds a target mRNA as a component of the RISC complex, and promotes cleavage of a target RNA by RISC. 9. A nucleic acid comprising an oligonucleotide strand of 21-23 nucleotides in length, wherein the oligonucleotide is sufficiently complementary to a target region of HAO1 mRNA having a sequence as set forth in SEQ ID NO: 1823 along at least 15 nucleotides of the oligonucleotide strand length to reduce HAO1 target mRNA expression when the nucleic acid is introduced into a cell expressing the HAO1 mRNA, and wherein the nucleic acid comprises one or more modified nucleotides. 10. A pharmaceutical composition comprising the nucleic acid of claim 1 and a pharmaceutically acceptable carrier. 11. A method for reducing expression of a target HAO1 gene in a cell comprising contacting the cell with a nucleic acid of claim 1 in an amount sufficient to reduce expression of a target HAO1 mRNA in the cell. 12. A method for reducing expression of a target HAO1 mRNA in a subject comprising administering a nucleic acid of claim 1 to a subject in an amount sufficient to reduce expression of a target HAO1 mRNA in the subject. 13. The method of claim 12, wherein the subject has primary hyperoxaluria 1 (PHI). 14. The method of claim 12, wherein administration of the nucleic acid to the subject results in a reduction in glycolate oxidase in the subject. 15. The method of claim 12, wherein administration of the nucleic acid to the subject results in a decrease in an accumulation of calcium oxalate deposits in the subject. 16. The method of claim 12, wherein administration of the nucleic acid to the subject results in a decrease in an accumulation of calcium precipitates in the kidney in the subject. 17. The method of claim 12, wherein administration of the nucleic acid to the subject results in an increase in a glycolate/creatinine ratio in urine of the subject. 18. The method of claim 12, wherein administration of the nucleic acid to the subject is performed at a dose in a range of 0.3 to 10 mg/kg. 19. The method of claim 12, wherein administration of the nucleic acid to the subject results in a reduction of HAO1 mRNA levels in the subject that are detectable at 29 days post-administration. 20. The method of claim 12, wherein administration of the nucleic acid to the subject results in at least an 80% reduction of HAO1 mRNA levels. 21. The method of claim 12, wherein administration of the nucleic acid to the subject is performed subcutaneously. 22. A pharmaceutical composition comprising the nucleic acid of claim 9, and a pharmaceutically acceptable carrier. 23. A method for reducing expression of a target HAO1 gene in a cell comprising contacting a cell in vitro with a nucleic acid of claim 9, in an amount sufficient to reduce expression of a target HAO1 mRNA in the cell. 24. A method for reducing expression of a target HAO1 mRNA in a subject comprising administering a nucleic acid of claim 9, to a subject in an amount sufficient to reduce expression of a target HAO1 mRNA in the subject. 25. The method of claim 24, wherein the subject has primary hyperoxaluria 1 (PHI). 26. The method of claim 24, wherein administration of the nucleic acid to the subject is performed at a dose in a range of 0.3 to 10 mg/kg. 27. The method of claim 24, wherein administration of the nucleic acid to the subject results in a reduction of HAO1 mRNA levels in the subject that are detectable at 29 days post-administration. 28. The method of claim 24, wherein administration of the nucleic acid to the subject results in at least an 80% reduction of HAO1 mRNA levels. 29. The method of claim 24, wherein administration of the nucleic acid to the subject is performed subcutaneously. 30. A method for treating a subject having primary hyperoxaluria 1 (PHI), the method comprising: administering to the subject a nucleic acid comprising a first strand and a second strand forming a duplex structure, wherein the first strand is 21 nucleotides in length and the second strand is 23 nucleotides in length, wherein the second strand is 100% complementary with the sequence as set forth in SEQ ID NO: 1823, wherein the second strand has a 3' overhang of 2 nucleotides in length, wherein a GalNac moiety is conjugated to the 3' terminal nucleotide of the first strand, and wherein administration of the nucleic acid to the subject results in a reduction of HAO1 mRNA levels in the subject.